In a 70-year-old woman with chronic kidney disease (estimated glomerular filtration rate 31 mL/min/1.73 m²), hyperuricemia (uric acid 8.6 mg/dL) and a history of hypertension, hypothyroidism, hyperlipidemia, non‑alcoholic steatohepatitis, gastroesophageal reflux disease, overweight, and lymphadenitis, is it appropriate to start finerenone (Kerendia) together with dapagliflozin (Farxiga)?

Starting Kerendia (Finerenone) with Farxiga (Dapagliflozin) in CKD G3b

Yes, it is appropriate to start both Kerendia and Farxiga together in this patient, provided her serum potassium is ≤4.8 mmol/L (≤5.3 mg/dL) and she is on a maximally tolerated RAS inhibitor (ACE inhibitor or ARB). This combination represents guideline-concordant, evidence-based therapy for CKD progression risk reduction 1.

Clinical Rationale

This 70-year-old woman with CKD stage G3b (eGFR 31 mL/min/1.73 m²) meets criteria for both medications based on the KDIGO 2024 guidelines:

Farxiga (Dapagliflozin) Indication

• Recommended for eGFR ≥20 mL/min/1.73 m² regardless of albuminuria status or diabetes presence 1
• The 2024 KDIGO guidelines provide a 1A recommendation (strongest level) for SGLT2 inhibitors in adults with CKD 1
• FDA-approved to reduce sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with CKD at risk of progression 2
• Dose: 10 mg once daily for CKD indication (not for glycemic control in this non-diabetic patient) 2

Kerendia (Finerenone) Indication

• Recommended for eGFR >25 mL/min/1.73 m² with albuminuria >30 mg/g despite maximum tolerated RAS inhibitor 1
• The 2024 KDIGO guidelines provide a 2A recommendation for nonsteroidal MRAs in this setting 1
• Critical prerequisite: You must document her albuminuria status (urine albumin-to-creatinine ratio). If UACR >30 mg/g (>3 mg/mmol), she qualifies for finerenone
• Dose: 10 mg once daily for eGFR 25-59 mL/min/1.73 m² 1

Combination Therapy is Explicitly Supported

Practice Point 3.8.2 from KDIGO 2024 specifically states: "A nonsteroidal MRA may be added to a RASi and an SGLT2i for treatment of T2D and CKD in adults" 1. While this practice point references type 2 diabetes, the mechanistic rationale and safety profile support use in non-diabetic CKD with albuminuria.

Pre-Initiation Requirements

Before Starting Either Medication:

1. Check Serum Potassium (CRITICAL for Kerendia)

• Must be ≤4.8 mmol/L (≤5.3 mg/dL) to initiate finerenone 1
• If K+ 4.9-5.5 mmol/L: Hold finerenone, optimize diet/medications, recheck
• If K+ >5.5 mmol/L: Do not start finerenone 1

2. Confirm Albuminuria Status

• Obtain urine albumin-to-creatinine ratio (UACR)
• Finerenone only indicated if UACR >30 mg/g (>3 mg/mmol) 1

3. Verify RAS Inhibitor Therapy

• Patient should be on maximum tolerated dose of ACE inhibitor or ARB before adding finerenone 1
• This is a prerequisite per KDIGO guidelines

4. Assess Volume Status

• Correct any volume depletion before starting Farxiga 2
• Particularly important in elderly patients and those on diuretics

Dosing Algorithm

Farxiga (Dapagliflozin)

• Start: 10 mg once daily 2
• Continue even if eGFR falls below 25 mL/min/1.73 m² during treatment 2
• Do NOT initiate if eGFR <25 mL/min/1.73 m² 2
• Withhold 3 days before major surgery or prolonged fasting 2

Kerendia (Finerenone) - IF UACR >30 mg/g AND K+ ≤4.8 mmol/L

• Start: 10 mg once daily (for eGFR 25-59 mL/min/1.73 m²) 1
• Check K+ at 1 month, then every 4 months 1
• If K+ rises to 4.9-5.5 mmol/L: Continue same dose, monitor K+ every 4 months
• If K+ rises >5.5 mmol/L: Hold finerenone, address hyperkalemia, restart at 10 mg when K+ ≤5.0 mmol/L 1

Monitoring Protocol

First Month After Initiation:

• Serum potassium at 1 month (for finerenone) 1
• Serum creatinine/eGFR at 2-4 weeks (standard for any CKD medication change)
• Blood pressure monitoring (both drugs lower BP)

Ongoing Monitoring:

• Potassium every 4 months if on finerenone 1
• eGFR monitoring per usual CKD care (not altered by SGLT2i initiation per Practice Point 3.7.3) 1
• Expect initial eGFR dip of 3-5 mL/min/1.73 m² with Farxiga—this is hemodynamic, not harmful, and does NOT require discontinuation 1

Critical Safety Considerations

Hyperkalemia Risk with Finerenone

• Most important safety concern when combining with RAS inhibitor 1
• Baseline hyperuricemia (8.6 mg/dL) is NOT a contraindication
• Hypertension actually supports use (both drugs lower BP)
• If hyperkalemia develops: Optimize diet (low potassium), consider potassium binders, adjust diuretics—do NOT immediately stop RAS inhibitor or finerenone unless K+ >5.5 mmol/L 1

SGLT2 Inhibitor Considerations

• Monitor for genital mycotic infections (more common in women) 2
• Ensure adequate hydration
• No diabetic ketoacidosis risk in non-diabetic patients
• Beneficial effect on uric acid: Farxiga will likely lower her uric acid from 8.6 mg/dL 3, 4

Drug Interactions

• Both medications are compatible with her other conditions (hypothyroidism, hyperlipidemia, NASH, GERD)
• No dose adjustments needed for her comorbidities
• Lymphadenitis history is not a contraindication

What If Albuminuria is Absent?

If you check UACR and it is <200 mg/g (<20 mg/mmol):

• Still start Farxiga (2B recommendation for eGFR 20-45 with low albuminuria) 1
• Do NOT start Kerendia (only indicated with albuminuria >30 mg/g) 1
• Ensure she's on RAS inhibitor for hypertension regardless 1

If UACR is ≥200 mg/g (≥20 mg/mmol):

• Definitely start Farxiga (1A recommendation) 1
• Start Kerenida if K+ ≤4.8 mmol/L and on max RAS inhibitor 1

Common Pitfalls to Avoid

1. Don't wait to start Farxiga—it's indicated at eGFR 31 regardless of albuminuria 1
2. Don't stop Farxiga if eGFR dips initially—this is expected and protective 1
3. Don't start Kerenida without checking potassium first—hyperkalemia is the limiting factor 1
4. Don't add Kerenida without confirming albuminuria—it's only indicated with UACR >30 mg/g 1
5. Don't discontinue RAS inhibitor to add these drugs—all three work synergistically 1
6. Don't forget that her elevated uric acid will likely improve with Farxiga—this is a bonus benefit 3, 4